Personalis

Declining Sequencing Costs Will Unlock Precision Oncology Growth

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

09 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

US$9.00

48.9% undervalued

16 Aug

US$4.60

-23.2%

2.0%

Author's Valuation

US$9.0

48.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$9.0

48.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

26.21%

Life Sciences revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.34%

Calculation

US$41.05m

Earnings '28

52.82x

PE Ratio '28

US$2.17b

Market Cap '28

US$2.17b

Market Cap '28

194.82m

No. shares '28

US$11.13

Share Price '28

US$11.13 Share Price '28

Discounted to 2025 @ 7.34% p.a.

US$9.00

Fair Value '25